Gyre Therapeutics (GYRE) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 24.6% versus a loss of 44.2%. Over five years, MNPR leads with a +184.5% price change compared with -77.5% for GYRE. Monopar Therapeutics is the larger company by market cap ($467.6 million vs $460.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | MNPR |
|---|---|---|
| Share price | $4.21 | $69.00 |
| Market cap | $460.79M | $467.60M |
| 1-day change | -6.86% | -1.84% |
| YTD return | -40.37% | +5.67% |
| 1-year return | -44.24% | -24.64% |
| 5-year return | -77.55% | +184.54% |
| Forward P/E | 70.17 | — |
| EPS (TTM) | $-0.31 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $116.59M | $0 |
| Revenue growth (YoY) | +10.24% | — |
| Net income (latest FY) | $9.88M | $-13.72M |
| Gross margin | 95.35% | — |
| Operating margin | 9.85% | — |
| Net margin | 8.47% | — |
| 52-week high | $9.14 | $124.82 |
| 52-week low | $3.97 | $50.07 |
| Distance from 52-week high | -53.94% | -44.72% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +343.47% | +88.65% |
| Average volume | 181.04K | 151.83K |
| Shares outstanding | 109.45M | 6.78M |
| Employees | 625 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed GYRE by 19.6 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
GYRE vs MNPR FAQ
Which is bigger, Gyre Therapeutics or Monopar Therapeutics?
Monopar Therapeutics (MNPR) is larger, with a market capitalization of $467.60M compared with $460.79M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GYRE or MNPR?
MNPR returned -24.64% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.